Chemical inhibitors of D15Ertd621e can be used to regulate its activity by targeting various signaling pathways and kinases that are responsible for its function. Staurosporine is known to broadly inhibit protein kinases, which are vital for phosphorylation processes within cells. By preventing these kinases from functioning, Staurosporine can inhibit the phosphorylation of D15Ertd621e, which is essential for its activity. Similarly, Bisindolylmaleimide I is more selective and specifically inhibits protein kinase C (PKC). Since PKC is involved in a myriad of cellular functions, the inhibition by Bisindolylmaleimide I can lead to decreased activity of D15Ertd621e if it relies on PKC-mediated signaling for its function. LY294002 and Wortmannin both target the PI3K/Akt pathway, which is another crucial cell-signaling pathway. The inhibition of this pathway by these chemicals can suppress the phosphorylation and subsequent activity of D15Ertd621e.
In addition to these, PD98059 and U0126 target the MAPK/ERK pathway by inhibiting MEK1/2, which can reduce the activity of D15Ertd621e if it is regulated by this pathway. The JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 both act on specific branches of the MAP kinase pathways, which can lead to inhibition of D15Ertd621e if it is a downstream target. Rapamycin acts by inhibiting mTOR, a central regulator of cell growth, and this inhibition can lead to the downregulation of D15Ertd621e activity if it is part of the mTOR signaling network. Chelerythrine, another PKC inhibitor, can also decrease D15Ertd621e activity by blocking the PKC pathway. Additionally, PP2, an inhibitor of Src family kinases, can lead to decreased activity of D15Ertd621e if it is regulated by Src kinases. Lastly, Y-27632 targets ROCK kinases and can reduce D15Ertd621e activity if this kinase is part of the regulatory mechanism for D15Ertd621e. Each inhibitor interacts with the signaling pathways that could modulate the function of D15Ertd621e, leading to a comprehensive approach for controlling its activity within the cellular context.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, and D15Ertd621e is known to be regulated by phosphorylation. Inhibition of these kinases can therefore inhibit the phosphorylation state of D15Ertd621e, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
This chemical is a specific inhibitor of protein kinase C (PKC), and since PKC-mediated signaling pathways are crucial for the function of many proteins, inhibiting PKC can lead to the inhibition of D15Ertd621e's activity if D15Ertd621e is regulated by PKC-dependent pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K/Akt pathway, a pathway that may regulate the activity of D15Ertd621e through phosphorylation. By inhibiting this pathway, the activity of D15Ertd621e can be decreased. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor which blocks the MAPK/ERK pathway. If D15Ertd621e is regulated by the ERK signaling pathway, inhibition of MEK can lead to inhibition of D15Ertd621e activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent PI3K inhibitor like Wortmannin can inhibit the PI3K/Akt pathway, which could be upstream of D15Ertd621e. By inhibiting this pathway, Wortmannin can reduce the activity of D15Ertd621e. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. Inhibition of JNK can lead to inhibition of downstream proteins regulated by this pathway, potentially including D15Ertd621e if it is a downstream effector. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, and by inhibiting p38 MAPK, it can inhibit the activity of proteins regulated by the p38 MAPK pathway, potentially including D15Ertd621e. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 and can inhibit the MAPK/ERK pathway. By doing so, it can inhibit the activity of D15Ertd621e if D15Ertd621e activity is dependent on this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. Inhibition of mTOR can lead to inhibition of downstream proteins that are regulated by mTOR signaling, potentially including D15Ertd621e. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a PKC inhibitor, and by inhibiting PKC, it can decrease the activity of proteins that are regulated by PKC signaling, potentially including D15Ertd621e. | ||||||